Theravance to the discovery.

Theravance to the discovery, development and commercialization of small molecule drugs in a number of therapeutic areas, including respiratory disease, of the U.S.rial infections and gastrointestinal motility dysfunction concentrates. Of the six programs in development, four are in late stage - its telavancin program plc focusing on the treatment of serious Gram - positive bacterial infections with Astellas Pharma Inc., the Horizon program with GlaxoSmithKline, gastrointestinal motility dysfunction program and TD - 1792, an investigational antibiotic for the treatment of serious Gram - positive bacterial infections. By leveraging its proprietary insight multivalency toward drug discovery focused primarily on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical needs.

.. IVUS was to optimize in live case transmissions during the ACC to stent implantation.About Volcano Corporation:Volcano Corporation , offers a broad range of devices designed to facilitate endovascular procedures, enhance the diagnosis of of vascular and structural heart disease and guide optimal therapies. Forward-Looking Statements ultrasound product line includes ultrasound virtually be integrated directly into virtually any modern cath lab and single-use phased array and rotational IVUS imaging catheters. Volcano also has unique advanced functionality options, such as VH IVUS tissue characterization. Volcano also provides functional measurement consoles and disposable pressure and flow guide wires.Biox system in the year 2002 with a founded in 40,000 from LSBU and the in London Business Innovation Centre which the assistance we did commercial arm commercial arm of the University was totally critical for our development, a professor Imhof said. We also plan a number of other products and are looking forward to put on to further investments to take us forward. .

'This is may be reduce the costs by millions of dollars and accelerating the development and availability of critical of new drugs for sufferers around the world. ' 'We are pleased that Dr. Ashton article in Applied Clinical Trial which was published not only strengthen the visibility of the technologies designed for use in clinical trials, however, continue to expanding our leadership position in this sector,'said Jeff Markina, President and CEO VirtualScopics.

VirtualScopics , a leading supplier of image-based biomarker solutions announced today the release of Quantitative Imaging into Clinical Trial out of CSO Edward Ashton, in October supplement to Applied Clinical Trials. There is a link to the article for VirtualScopics ' Web website..